Risks of Intermittent Fasting in Patients With Primary Adrenal Insufficiency

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-03-04

Study Completion Date

2024-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In primary adrenal insufficiency, there is an increased risk of hypoglycaemia and dehydration. These risks have been little studied particularly during intermittent fasting. The present study aimed to assess these risks in a prospective study of 30 subjects with primary adrenal insufficiency. Patients will undergo a clinical examination, blood sampling and continuous glucose monitoring for fourteen days (one week of fasting and one week of non-fasting).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hypoglycaemia (Low Blood Sugar) in Adults With Diabetes and Adrenal Failure

NCT05806190

Diabetes Mellitus, Type 1 Adrenal Insufficiency Diabetes Mellitus Type 2 - Insulin-Treated

COMPLETED

Diagnosing and Treating Low Blood Sugar Levels

NCT00001276

Hypoglycemia Insulinoma

RECRUITING

Study of the Impact of HYPOglycaemia on Sarcopenia in CIRrhosis

NCT06948656

Cirrhosis

RECRUITING

Associated Factors in Perioperative Hypoglycemia in Patients With Diabetes

NCT00826007

Diabetes Hypoglycemia

COMPLETED

Hypoglycemia in Hospitalized Patients

NCT02228642

Diabetes Hypoglycemia

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The risk of hypoglycaemia in primary adrenal insufficiency (PAI) is well known but has been only few studied. It is explained by cortisol insufficiency. Only a few publications concerned this subject. The risk of hypoglycaemia seems to be increased during acute decompensation, following cessation of treatment and during fasting or delayed food intake. So, this risk would be increased during intermittent fasting such as the Ramadan fast. A previous study carried out in the endocrinology department of La Rabta University Hospital involving 30 subjects with secondary adrenal insufficiency who were monitored by continuous glucose monitoring (CGM) for 24 hours showed three cases of hypoglycaemia during intermittent fasting and no hypoglycaemia outside fasting. Studies assessing the risks of intermittent fasting concerned subjects with secondary adrenal insufficiency. No study assessed the risks of intermittent fasting in PAI. Furthermore, given the mineralocorticoid deficiency in PAI, there is also a risk of dehydration and hypotension.

Aims of the study:

Overall objective: to assess the risks of intermittent fasting in subjects with primary adrenal insufficiency.

Specific objectives:

* To assess the frequency of hypoglycaemia in subjects with primary adrenal insufficiency during fasting and outside fasting.
* To assess the frequency of dehydration in subjects with primary adrenal insufficiency during fasting and outside fasting.
* To study the factors associated with hypoglycaemia and dehydration.

Methods :

Type of study: prospective, cross over, comparative study with subjects taken as their own controls.

A group of 15 patients will be studied during the week preceding the month of Ramadan (non fasting week) and the first week of Ramadan (fasting week). A group of 15 patients will be studied during the fourth week of Ramadan (fasting week) and the first week after Ramadan (non fasting week). The analysis will thus concern 210 fasted days and 210 non-fasted days.

The included patients will be examined on two occasions 14 days apart. Visit 1 will include a clinical examination, the setting up of the continuous glucose monitoring system, a fasting blood sampling and the delivery of monitoring sheets.

Clinical data:

* Demographic data: age, gender
* Data relating to PAI: age, aetiology, replacement therapy. Fasting history and course (number of days fasted, occurrence of complications).
* Quality of life and quality of sleep questionnaire.
* weight, height, waist circumference, supine and standing blood pressure, heart rate, presence of melanoderma, signs of dehydration.

The patient will be given dietary and hygiene advice on fasting and the treatment (gluco- and mineral-corticosteroids) will be adjusted if necessary, in accordance with the recommendations published in 2021 and 2022.

Biological data: urea, iono

During the study period (two weeks), patients will be asked to fill in a monitoring form which will include details of medication taken, waking and bedtimes, physical activity and the occurrence of any discomfort (asthenia, signs of hypoglycaemia, signs of arterial hypotension or other).

Patients will be monitored during the fasting period by one of the investigators by telephone in order to check compliance with the protocol and the possible occurrence of complications.

Criteria for breaking the fasting: occurrence of malaise during fasting, hypoglycaemia diagnosed by CGM, elevation of urea or hyperkalaemia.

Visit 2 : the patients will undergo a clinical examination including quality of life and quality of sleep questionnaires and a physical examination, fasting blood sampling, recovery of the continuous glucose monitoring system and monitoring sheets.

Diagnosis criteria:

* Hypoglycaemia is defined as interstitial glucose measured during CGM \< 2.8mmol/l.
* Dehydration is defined by the presence of arterial hypotension (BP \<9/6cmHg or orthostatic hypotension) or elevated plasma urea.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Primary Adrenal Insufficiency Intermittent Fasting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Non fasting

Non fasting arm: usual diet and behavior

Group Type NO_INTERVENTION

No interventions assigned to this group

Fasting

Intermittent fasting

Group Type EXPERIMENTAL

intermittent fasting

Intervention Type BEHAVIORAL

fasting from predawn to sunset (no eating and no drinking), for approximately 16 hours.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

intermittent fasting

fasting from predawn to sunset (no eating and no drinking), for approximately 16 hours.

Intervention Type BEHAVIORAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Ramadan fasting

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Primary adrenal insufficiency
* Disease duration of at least one year
* Substituted with hydrocortisone and fludrocortisone
* Wishing to fast during the month of Ramadan 2024

Exclusion Criteria

* Diabetes mellitus
* Renal insufficiency
* Hepatic insufficiency
* Cardiac insufficiency
* Respiratory insufficiency
* Use of hypoglycaemic agents
* Use of diuretics
* Use of glucocorticoids other than those prescribed for replacement
* Poor control of the disease (asthenia, malaise, melanoderma, discontinuation of treatment, etc.)
* Pregnancy
* Breast-feeding.

Minimum Eligible Age

20 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No